2-bromo-4-nitro-1-(2,2,2-trifluoro-ethoxy)-benzene | 710351-85-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-4-nitro-1-(2,2,2-trifluoro-ethoxy)-benzene
• 英文别名: 3-Bromo-4-(2,2,2-trifluoroethoxy)nitrobenzene；2-bromo-4-nitro-1-(2,2,2-trifluoroethoxy)benzene
• CAS: 710351-85-2
• 化学式: C₈H₅BrF₃NO₃
• 分子量: 300.032
• InChiKey: CYIHRGAJIPHNIM-UHFFFAOYSA-N

物化性质

• 沸点：
  300.3±42.0 °C(Predicted)
• 密度：
  1.720±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-bromo-4-nitro-1-(2,2,2-trifluoro-ethoxy)-benzene 在 氮气 、 钯 作用下， 以 乙酸乙酯 为溶剂， 反应 16.0h， 生成 3-bromo-4-(2,2,2-trifluoro-ethoxy)-phenylamine
  参考文献：
  名称：

  SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE

  摘要：

  提供了新的取代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新的化合物组合物可以单独使用或与至少一种额外的药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。

  公开号：

  US20120288501A1
• 作为产物：
  描述：

  2,2,2-三氟乙醇 、 3-溴-4-氟硝基苯 在 potassium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 18.0h， 以80%的产率得到2-bromo-4-nitro-1-(2,2,2-trifluoro-ethoxy)-benzene
  参考文献：
  名称：

  Substituted benzazoles and methods of their use as inhibitors of Raf kinase

  摘要：

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。

  公开号：

  US20040122237A1

文献信息

• Substituted benzazoles and methods of their use as inhibitors of raf kinase
  申请人：Novartis AG

  公开号：US08299108B2

  公开（公告）日：2012-10-30

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的取代苯唑化合物、组成和抑制人或动物体内Raf激酶活性的方法。这些新化合物组成可以单独使用，也可以与至少一种额外的药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors
  作者：Shulun Chen、Wei Guo、Xiaohua Liu、Pu Sun、Yi Wang、Chunyong Ding、Linghua Meng、Ao Zhang

  DOI：10.1016/j.ejmech.2019.06.037

  日期：2019.10

  Indoleamine 2, 3-dioxygenase 1 (IDO1) plays a key role in tryptophan catabolism which is an important mechanism in immune tolerance. The small molecule epacadostat is the most advanced IDO1 inhibitor, but its phase III trials as a single agent or in combinations with PD-1 antibody failed to show appreciable objective responses. To gain more insight on the antitumor efficacy of IDO1 inhibitors, we have designed a series of analogues of epacadostat by incorporating a cyclic aminosulfonamide moiety as the sidechain capping functionality. Compound 5a was found to display significant potency against recombinant hIDO1 and hIDO1 expressed HEK293 cancer cells. This compound has improved physico-chemical properties, acceptable PK parameters as well as optimal cardiac safety. Similar to epacadostat, 5a is ineffective as single agent in the CT-26 syngeneic xenograft model, however, the combination of 5a with PD-1 antibody showed both elevated tumor growth inhibition and prolonged median life span. (C) 2019 Elsevier Masson SAS. All rights reserved.
• US8299108B2
  申请人：——

  公开号：US8299108B2

  公开（公告）日：2012-10-30
• Substituted benzazoles and methods of their use as inhibitors of Raf kinase
  申请人：——

  公开号：US20040122237A1

  公开（公告）日：2004-06-24

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。
• SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
  申请人：Amiri Payman

  公开号：US20120288501A1

  公开（公告）日：2012-11-15

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的取代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新的化合物组合物可以单独使用或与至少一种额外的药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。